Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and lethal disorder of the blood in which the body attacks and destroys red blood cells in massive amounts. This focus collection and short ...
Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...
AJMC ®: Paroxysmal nocturnal hemoglobinuria (PNH) is 1 of several complement-driven diseases. Can you describe its clinical presentation? DE CASTRO: PNH presents heterogeneously. One of the 3 ...
NEW ORLEANS -- The targeted factor B inhibitor iptacopan improved hemoglobin (Hb) levels and led to high rates of freedom from transfusion in patients with paroxysmal nocturnal hemoglobinuria (PNH) ...
Carlos M. De Castro, MD, highlights the phase III Apply-PNH study presented at ASH 2022. Carlos M. De Castro, MD: In PNH [paroxysmal nocturnal hemoglobinuria], the needs are 2-fold. Over the past 20 ...
The US Food and Drug Administration has approved danicopan (Voydeya, AstraZeneca) as an add-on therapy to treat extravascular hemolysis in adults receiving ravulizumab or eculizumab for paroxysmal ...
Voydeya is a first-in-class, oral, factor D inhibitor. The Food and Drug Administration (FDA) has approved Voydeya ™ (danicopan) as add-on therapy to ravulizumab or eculizumab for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results